{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:30:21Z","timestamp":1794069021731,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.kint.2021.06.013","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T04:54:06Z","timestamp":1624769646000},"page":"684-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)"],"prefix":"10.1016","volume":"100","author":[{"given":"Ronald D.","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Watnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Hallows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Lalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana C.","family":"Miskulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Seliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyongtae Ty","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.06.013_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.06.013_bib2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.06.013_bib3","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.06.013_bib4","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A\u00a0practical guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.06.013_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.06.013_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrendo.2014.102","article-title":"The management of patients with polycystic ovary syndrome","volume":"10","author":"Jayasena","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.kint.2021.06.013_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2021.06.013_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2021.06.013_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","article-title":"The LKB1 tumor suppressor negatively regulates mTOR signaling","volume":"6","author":"Shaw","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.kint.2021.06.013_bib11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib12","doi-asserted-by":"crossref","first-page":"C1297","DOI":"10.1152\/ajpcell.00227.2002","article-title":"Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells","volume":"284","author":"Hallows","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kint.2021.06.013_bib13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI9622","article-title":"Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase","volume":"105","author":"Hallows","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.06.013_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MNH.0b013e3283562390","article-title":"AMP-activated protein kinase regulation of kidney tubular transport","volume":"21","author":"Pastor-Soler","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2021.06.013_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.kint.2021.06.013_bib16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.06.013_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2021.06.013_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2021.06.013_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline","volume":"94","author":"Cryer","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2021.06.013_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A\u00a0randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2021.06.013_bib23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2021.06.013_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.kint.2019.08.038","article-title":"Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease","volume":"97","author":"Hopp","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.06.013_bib25","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41431-020-00806-5","article-title":"The genetic landscape of polycystic kidney disease in Ireland","volume":"29","author":"Benson","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.kint.2021.06.013_bib27","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.kint.2021.06.013_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease","volume":"7","author":"Revicki","year":"1998","journal-title":"Qual Life Res"},{"key":"10.1016\/j.kint.2021.06.013_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2251-6581-12-17","article-title":"Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified?","volume":"12","author":"Kibirige","year":"2013","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"10.1016\/j.kint.2021.06.013_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1752-8062.2011.00347.x","article-title":"Recommendations for planning pilot studies in clinical and translational research","volume":"4","author":"Moore","year":"2011","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.kint.2021.06.013_bib32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.kint.2021.06.013_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.06.013_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","article-title":"Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"73","author":"Smith","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.06.013_bib35","series-title":"Qualification of biomarker total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease","year":"2015"},{"key":"10.1016\/j.kint.2021.06.013_bib36","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821006013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821006013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:59:23Z","timestamp":1758761963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821006013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0085253821006013"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.06.013","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}